Aduro BioTech Inc (NASDAQ:ADRO) CEO Stephen T. Isaacs sold 31,098 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $1.31, for a total transaction of $40,738.38. Following the sale, the chief executive officer now owns 295,926 shares of the company’s stock, valued at approximately $387,663.06. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Shares of ADRO stock opened at $1.22 on Friday. The firm has a market capitalization of $103.38 million, a PE ratio of -1.05 and a beta of 1.48. The firm has a fifty day simple moving average of $1.31 and a two-hundred day simple moving average of $2.50. The company has a current ratio of 8.45, a quick ratio of 8.45 and a debt-to-equity ratio of 0.32. Aduro BioTech Inc has a 12 month low of $1.15 and a 12 month high of $7.64.

Aduro BioTech (NASDAQ:ADRO) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.05). Aduro BioTech had a negative net margin of 624.51% and a negative return on equity of 68.69%. The business had revenue of $4.89 million for the quarter, compared to the consensus estimate of $4.56 million. On average, equities analysts predict that Aduro BioTech Inc will post -0.95 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of ADRO. JPMorgan Chase & Co. grew its stake in shares of Aduro BioTech by 196.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,414,065 shares of the biotechnology company’s stock worth $2,474,000 after acquiring an additional 937,166 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Aduro BioTech by 56.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,812,200 shares of the biotechnology company’s stock worth $2,791,000 after acquiring an additional 653,600 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Aduro BioTech by 75.8% in the 2nd quarter. AQR Capital Management LLC now owns 701,608 shares of the biotechnology company’s stock worth $1,080,000 after acquiring an additional 302,573 shares in the last quarter. Baillie Gifford & Co. grew its stake in shares of Aduro BioTech by 6.2% in the 2nd quarter. Baillie Gifford & Co. now owns 4,070,724 shares of the biotechnology company’s stock worth $6,269,000 after acquiring an additional 239,298 shares in the last quarter. Finally, BlackRock Inc. grew its stake in shares of Aduro BioTech by 4.4% in the 2nd quarter. BlackRock Inc. now owns 5,225,866 shares of the biotechnology company’s stock worth $8,046,000 after acquiring an additional 220,010 shares in the last quarter. Hedge funds and other institutional investors own 41.69% of the company’s stock.

ADRO has been the subject of a number of recent research reports. Cowen restated a “buy” rating on shares of Aduro BioTech in a research note on Friday, August 2nd. CIBC restated a “market perform” rating on shares of Aduro BioTech in a research note on Monday, June 3rd. Oppenheimer lowered shares of Aduro BioTech from an “outperform” rating to a “market perform” rating in a research note on Monday, June 3rd. Finally, ValuEngine upgraded shares of Aduro BioTech from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $8.01.

Aduro BioTech Company Profile

Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.

Further Reading: Quiet Period Expirations Explained

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.